Inthera Bioscience

Frank Hennecke, PHD

Head of CMC Development

Frank Hennecke has been serving as Head of CMC Development for Inthera since January 2020. Frank has 20+ years of experience in biopharmaceutical drug development, production, and clinical supply. He has held executive positions in several publicly-traded and privately held biotech companies. He has developed 20+ investigational drug candidates, including protein, peptide, oligonucleotide (DNA, siRNA), and virus-like particle (VLP)-based pharmaceuticals, into preclinical and clinical studies. Frank has proven track record for expeditiously moving investigational drug candidates into and through clinical phases and in successful completion of transactions incl. M&A.